Clinical evaluation of pancreatic excretion test with dimethadione and oral BT-PABA test in chronic pancreatitis.
Further evaluation of the pancreatic excretion test with 5,5-dimethyl-2,4-oxazolidinedione (dimethadione, DMO) was made in comparison with the pancreozymin-secretin (PS) test on 100 normal subjects, 79 patients with chronic pancreatitis, and 83 patients with nonpancreatic disease. The diagnostic sensitivity of the oral N-benzoyl-L-tyrosyl-PABA (BT-PABA) test was estimated in 42 patients with chronic pancreatitis, on whom both PS and DMO excretion tests were performed as test of reference for exocrine pancreatic function. Pancreatic DMO excretion after secretin injection was significantly diminished in chronic pancreatitis. The DMO excretion test was more sensitive than the PS test to detect chronic pancreatitis and to distinguish between mild to moderate and advanced noncalcific chronic pancreatitis. The specificity of the DMO excretion test was more than adequate to find out pancreatic disease. The 6-hr urinary PABA excretion was significantly reduced in chronic pancreatitis. The BT-PABA test, however, showed the low sensitivity in mild to moderate chronic pancreatitis.
D010129:4-Aminobenzoic Acid / Q000652:urine*; D000328:Adult; D062365:Aminobenzoates / Q000652:urine*; D002908:Chronic Disease; D004114:Dimethadione / Q000652:urine*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010080:Oxazoles / Q000652:urine*; D010195:Pancreatitis / Q000175:diagnosis / Q000652:urine*; D062366:para-Aminobenzoates
D062365:Aminobenzoates; D010080:Oxazoles; D062366:para-Aminobenzoates; C006717:bentiromide; D004114:Dimethadione; D010129:4-Aminobenzoic Acid